Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Recent advances in drug discovery against Mycobacterium tuberculosis: Metal-based complexes

Texto completo
Autor(es):
Scarim, Caue Benito [1] ; de Farias, Renan Lira [2] ; de Godoy Netto, Adelino Vieira [2] ; Chin, Chung Man [1, 3] ; dos Santos, Jean Leandro [2, 1] ; Pavan, Fernando Rogerio [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Inst Chem, BR-14800900 Araraquara, SP - Brazil
[3] Union Coll Great Lakes UNILAGO, Sch Med, BR-15030070 Sao Jose Do Rio Preto, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo de Revisão
Fonte: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY; v. 214, MAR 15 2021.
Citações Web of Science: 0
Resumo

Metal-based drugs are privileged motifs that act as primary pharmacophores in bioactive compounds for various diseases, including tuberculosis (TB). This potentially life-threatening and extremely contagious infectious disease is caused by Mycobacterium tuberculosis (Mtb). In 2018, TB infected about 10 million people and caused 1.2 million deaths worldwide. A large number of ligands are promising scaffolds in drug design, including heterocyclic, phosphines, schiff bases, thio and semicarbazones, aliphatic amines, cyclopalladated, cyanometallates and miscellaneous. Moreover, several metal-based complexes have been studied for the treatment of numerous illnesses, including infectious diseases. To contribute to drug design, we identified the metal-based organometallic complexes against Mtb. Thus, in this review article, we analysed the recent contributions of metal-based scaffolds for design of new anti-Mtb drugs in the last decade (2011-2020). Besides, metal-based approaches will be presented in order to find out new antitubercular agents. (C) 2021 Elsevier Masson SAS. All rights reserved. (AU)

Processo FAPESP: 16/10847-9 - Hidroximetilnitrofural (NFOH): estudo da atividade em fase crônica da Doença de Chagas em modelo animal e síntese de derivados solúveis
Beneficiário:Cauê Benito Scarim
Modalidade de apoio: Bolsas no Brasil - Doutorado